FibroGen, Inc.

NasdaqGS:FGEN Lagerbericht

Marktkapitalisierung: US$111.4m

FibroGen Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Thane Wettig

Geschäftsführender

US$3.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts15.7%
Amtszeit als Geschäftsführerless than a year
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements2.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.3yrs

Jüngste Management Updates

Recent updates

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 06

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

May 28

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

May 07
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22
FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24
A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18
Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12
The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06
Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31
Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05
Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08
Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat

Aug 12
News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat

Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term

Jul 17
Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term

Is FibroGen A Buy Going Into Roxa AdCom?

Jul 13

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Thane Wettig im Vergleich zu den Einnahmen von FibroGen verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$4mUS$573k

-US$284m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$322m

Mar 31 2023n/an/a

-US$307m

Dec 31 2022US$3mUS$535k

-US$294m

Sep 30 2022n/an/a

-US$362m

Jun 30 2022n/an/a

-US$220m

Mar 31 2022n/an/a

-US$281m

Dec 31 2021US$3mUS$510k

-US$290m

Sep 30 2021n/an/a

-US$215m

Jun 30 2021n/an/a

-US$231m

Mar 31 2021n/an/a

-US$183m

Dec 31 2020US$4mUS$263k

-US$189m

Geschäftsführer

Thane Wettig (59 yo)

less than a year

Amtszeit

US$3,640,829

Vergütung

Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Thane Wettig
CEO & Directorless than a yearUS$3.64m0.19%
$ 212.2k
Juan Graham
Senior VP & CFO2.8yrsUS$3.09m0.065%
$ 72.3k
Christine Chung
Senior Vice President of China Operations17.4yrsUS$3.11m0.32%
$ 360.4k
Barry Berkowitz
Founder29.4yrskeine Datenkeine Daten
John Hunter
Chief Scientific Officer2.9yrskeine Datenkeine Daten
David DeLucia
Vice President of Corporate FP&A and Investor Relationsno datakeine Datenkeine Daten
Michael Lowenstein
Chief Legal Officer8.2yrskeine Datenkeine Daten
Tricia Stewart
Chief People Officer3.1yrskeine Datenkeine Daten
Kirk Christoffersen
Chief Business Officer3.6yrskeine Datenkeine Daten
Rahul Kaushik
Senior Vice President of Pharmaceutical Development2.4yrskeine Datenkeine Daten
Elizabeth Bearby
Senior VP of Regulatoryless than a yearkeine Datenkeine Daten
Deyaa Adib
Senior VP & Chief Medical Officerless than a yearkeine Datenkeine Daten

2.9yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Thane Wettig
CEO & Directorless than a yearUS$3.64m0.19%
$ 212.2k
George Martin
Chairman of Scientific Advisory Boardno datakeine Datenkeine Daten
Suzanne Blaug
Independent Director5yrsUS$388.03k0.021%
$ 23.9k
Jeffrey Edwards
Independent Director8.7yrsUS$385.53k0.026%
$ 28.8k
James Schoeneck
Independent Chairman of the Board14.2yrsUS$499.58k0.082%
$ 91.3k
Gerald Lema
Independent Director6.8yrsUS$383.03k0.037%
$ 41.5k
Maykin Ho
Independent Director5.5yrsUS$375.53k0.023%
$ 26.0k
Benjamin Cravatt
Independent Director3.8yrsUS$392.55k0.021%
$ 22.9k
Aoife Brennan
Independent Director3.8yrsUS$373.03k0.020%
$ 22.0k

5.3yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter